Currently, new anti-carbapenem-resistant Enterobacteriaceae (CRE) antibiotics are estimated to treat 35 percent of CRE infections in which they were expected to be used as first-line agents...
According to the U.S. Centers for Disease Control and Prevention there are at least two million people in the country who become infected with a bacteria that are resistant to antibiotics